December 12, 2014Open Access

Newborn Screening for Congenital Adrenal Hyperplasia in New Zealand, 1994–2013

Key Points

Key points are not available for this paper at this time.

Abstract

Screening alone accounted for nearly 50% cases of CAH detected in the newborn period, including a fifth of affected females, indicating that clinical diagnosis is unreliable in both genders. Symptoms were mild at diagnosis and there were no adrenal crises. This study confirms the benefits of newborn CAH screening.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Heather et al. (Fri,) studied this question.

synapsesocial.com/papers/69d89ce0a5ecc596b5d17e29 https://doi.org/https://doi.org/10.1210/jc.2014-3168

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening2013 · 23 citations
2Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency2000 · 876 citations
3Neonatal screening for congenital adrenal hyperplasia2004 · 128 citations
4How Many Deaths Can Be Prevented by Newborn Screening for Congenital Adrenal Hyperplasia?2006 · 101 citations
5Use of Steroid Profiling by UPLC-MS/MS as a Second Tier Test in Newborn Screening for Congenital Adrenal Hyperplasia: The Utah Experience2009 · 100 citations

Perguntar à IA

Bookmark

View Full Paper